The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Evelyn H. Orlando,Patrick Gould, Brian Cuzzo,Maegan Ford, Yuxuan Chen,Alexander Sanjurjo, Benjamin May,Demetra Tsapepas,Rebecca J. Leeman-Neill,Govind Bhagat,Geoffrey Dube,Heather Morris,Selim Arcasoy,Farhana Latif,Mercedes Martinez,Marcus Pereira,Andrew H. Lipsky,Ahmed Sawas,Ran Reshef,Barbara Pro

Blood（2023）

引用 0|浏览7

暂无评分

摘要

The association between Epstein-Barr Virus (EBV) reactivation after solid organ transplantation (SOT) and Post-Transplant Lymphoproliferative Disorder (PTLD) is well described. There are currently no guidelines regarding the use of rituximab preemptively in patients with EBV viremia after SOT to reduce the risk of PTLD. We sought to determine whether rituximab in SOT patients with EBV viremia has benefit in preventing PTLD.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要